Xmtherapeutics
Founded 2022 · 3 employees on LinkedIn · 1 known investors
XM Therapeutics develops therapeutics that target and repair the extracellular matrix (ECM) to treat chronic diseases. Its platform identifies biological mechanisms for modulating and restoring abnormal ECM directly.
Also known as XM Therapeutics · XM Therapeutics, Inc.
Investors · 1
Company profile
researched Aug 2026XM Therapeutics, Inc. is a privately-held Delaware corporation based at 225 Dyer St in Providence, Rhode Island, working on therapies that act on the extracellular matrix (ECM), the network of macromolecules that provides structural support in the body and regulates cell communication, cell behavior and tissue growth. The company's stated premise is that ECM repair mechanisms activated by injury or disease can fail to switch off, contributing to chronic disease, organ scarring and inflammation, and that human ECM particles can instead be harnessed to guide tissue repair in damaged hearts, chronic wounds and scarred joints.
Its research identifies biological mechanisms for repairing and modulating abnormal ECM, and its therapeutic platform is described as targeting and restoring the ECM directly. Website sections point to focus areas including heart disease and the repair of scarred tissue, and reference the use of newer technologies such as proteomic profiling and artificial intelligence to characterize the ECM. The company is classified in the biotechnology industry and described as developing tissue repair and regeneration platforms for chronic disorders.
Business model
Preclinical-stage therapeutics developer seeking Seed and Series A investment, and open to partnerships covering specific therapeutic indications, complementary and enabling technologies, and production scaling.
Traction
Named in September 2025 as one of five foundational members of Ocean State Labs, Rhode Island's first life science incubator, managed by Portal Innovations and developed in partnership with Brown University. Peer-reviewed research associated with the company was published in the American Journal of Physiology-Heart and Circulatory Physiology in February 2025 on lab-grown 3D ECM particles improving cardiac function and morphology in myocardial ischemia.
Latest developments
In September 2025 the Rhode Island Life Science Hub announced XM Therapeutics among the inaugural members of Ocean State Labs, a more than 30,000 square foot incubator scheduled to open in the first quarter of 2026. As of the company's site, XM Therapeutics is seeking Seed and Series A investors.
▸Full profile — market position, technology, go-to-market, geography
Market position
Early-stage biotech positioned within an ECM-focused research and commercial community spanning research institutions, biotech startups and pharmaceutical companies, with applications in regenerative medicine, fibrosis, oncology, biomarkers and analytical methods.
Technology
A therapeutic platform based on the extracellular matrix, including lab-grown, human three-dimensional ECM particles; associated research reports that such particles improved cardiac function and morphology in an animal model of myocardial ischemia. Proteomic profiling and AI are cited as enabling tools for characterizing the ECM.
Go-to-market
Direct outreach to investors (invest@xmtherapeutics.com) with whitepaper, technology platform and business plan materials, and to prospective collaborators (partners@xmtherapeutics.com) for joint scientific and commercial development.
Patients with chronic diseases involving abnormal ECM, including damaged hearts, chronic wounds and scarred joints; commercially, pharmaceutical and biotech partners and research institutions.
Geography
United States; headquartered in Providence, Rhode Island, with membership in the Ocean State Labs incubator in Providence's Innovation District.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsThe Rhode Island Life Science Hub announced XM Therapeutics, described as developing tissue repair and regeneration platforms for chronic disorders, as one of five inaugural members of Ocean State Labs, Rhode Island's first life science incubator, managed by Portal Innovations and slated to open in Q1 2026.
A paper associated with the company in the American Journal of Physiology-Heart and Circulatory Physiology reported that lab-grown, human 3D extracellular matrix particles improved cardiac function and morphology in an animal model of myocardial ischemia.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Xmtherapeuticsxmtherapeutics.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Xmtherapeutics do?
- XM Therapeutics is a Providence, RI biotech developing therapies that repair the extracellular matrix to treat chronic diseases.
- Who are Xmtherapeutics's investors?
- Xmtherapeutics's investors include Slater Technology Fund.